Research
Hormonal
Structured aerobic, resistance, or combined exercise training for at least 12 weeks significantly improves glycemic control (HbA1c reduction of 0.51-0.73%) in patients with Type 2 Diabetes.
Engage in structured exercise (aerobic, resistance, or both) for at least 12 weeks. Aim for more than 2.5 hours per week for maximum blood sugar benefits. Start with lower intensities if new to exercise.
GoodSupportsHIGH confidence
Unter einem strukturierten, begleiteten Ausdauer-, Kraft- oder einem kombinierten Training von mindestens 12 Wochen Dauer lässt sich die glykämische Stoffwechsellage in klinisch relevantem Ausmaß verbessern. Beim aeroben Ausdauertraining reduzierte sich der HbA1c-Wert um durchschnittlich 0,73 %, beim Kraftausdauertraining um 0,57 % und beim kombinierten Training um 0,51 %.
Why this rating
Based on a meta-analysis of 8538 patients and multiple reviews cited.
Source
Körperliche Aktivität und Sport bei Typ-2-Diabetes
Andreas M. Nieß et al. · Diabetologie und Stoffwechsel · 2017
DOI 10.1055/s-0042-121407
narrative_reviewCited 10×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Regular physical activity reduces cardiovascular mortality and all-cause mortality in patients with Type 2 Diabetes.Good
- Prolonged sitting is an independent risk factor for Type 2 Diabetes, cardiovascular mortality, and all-cause mortality.Good
- High-Intensity Interval Training (HIT) may improve insulin sensitivity more effectively than moderate-intensity continuous training (MICT) in some studies, though evidence is less extensive.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →